Jammal Millena Prata, Lopes Ananda Domingues, Etchebehere Renata Margarida, Murta Eddie Fernando Candido, Nomelini Rosekeila Simões
Research Institute of Oncology (IPON)/Department of Gynecology and Obstetrics, Federal University of Triângulo Mineiro, Uberaba, Brazil.
Surgical Pathology Service, Federal University of Triângulo Mineiro, Uberaba, Brazil.
J Obstet Gynaecol. 2022 Oct;42(7):3094-3100. doi: 10.1080/01443615.2022.2099736. Epub 2022 Jul 22.
The objectives of this study were to investigate the immunohistochemical expression of markers of mast cells and M2 macrophages in benign and malignant ovarian neoplasms and to examine the prognostic value of this expression in ovarian cancer. The study was performed with samples from 32 patients, divided into benign ( = 16) and malignant ( = 16) neoplasm groups. Samples obtained by surgical resection were submitted to immunohistochemical analysis. Higher proportions of M2 macrophages ( = .041) and mast cells ( = .0054) were present in malignant than benign ovarian neoplasms. Histological grade 2/3 was related to higher proportions of M2 macrophages compared with grade 1 ( = .0102). Stages II-IV were also related to higher proportions of M2 macrophages ( = .0102). Logistic regression revealed that M2 macrophages predicted malignancy [odds ratio (OR) = 1.017; 95% confidence interval (CI), 1.003-1.037; = .017], but that mastocytes had greater predictive value for this outcome (OR = 1.127; 95% CI, 1.018-1.105; = .013). M2 macrophages predicted more advanced histological grades (OR = 1.060; 95% CI, 1.010-1.218; = .003). The proportions of M2 macrophages and mast cells were greater in malignant than in benign ovarian neoplasms. Larger proportions of cells expressing M2 macrophages were related to more advanced histological grades and disease stages, and thus to worse prognoses for ovarian cancer.Impact Statement Concentrations of mast cells and M2 macrophages have been observed in several tumour types, but their significance remains uncertain. The proportions of M2 macrophages and mast cells were greater in malignant than in benign ovarian neoplasms. Larger proportions of cells expressing M2 macrophages were related to higher histological grades and more advanced stages of the disease. Larger proportions of cells expressing M2 macrophages were related to worse prognoses for malignant ovarian neoplasia. The discovery of new prognostic factors in ovarian cancer may be the target of studies on new treatments and immunotherapies for this disease. In addition, it can help guide the oncologist towards more aggressive treatments for patients with worse prognostic factors.
本研究的目的是调查肥大细胞和M2巨噬细胞标志物在良性和恶性卵巢肿瘤中的免疫组化表达，并检验这种表达在卵巢癌中的预后价值。该研究对32例患者的样本进行，分为良性肿瘤组（n = 16）和恶性肿瘤组（n = 16）。手术切除获得的样本进行免疫组化分析。与良性卵巢肿瘤相比，恶性卵巢肿瘤中M2巨噬细胞（P = 0.041）和肥大细胞（P = 0.0054）的比例更高。与1级相比，2/3级组织学分级与更高比例的M2巨噬细胞相关（P = 0.0102）。II-IV期也与更高比例的M2巨噬细胞相关（P = 0.0102）。逻辑回归显示，M2巨噬细胞可预测恶性肿瘤[比值比（OR）= 1.017；95%置信区间（CI），1.003 - 1.037；P = 0.017]，但肥大细胞对这一结果具有更大的预测价值（OR = 1.12）。M2巨噬细胞可预测更高级别的组织学分级（OR = 1.060；95% CI，1.010 - 1.218；P = 0.003）。与良性卵巢肿瘤相比，恶性卵巢肿瘤中M2巨噬细胞和肥大细胞的比例更高。表达M2巨噬细胞的细胞比例更高与更高级别的组织学分级和疾病分期相关，因此与卵巢癌更差的预后相关。
在几种肿瘤类型中已观察到肥大细胞和M2巨噬细胞的浓度，但其意义仍不确定。与良性卵巢肿瘤相比，恶性卵巢肿瘤中M2巨噬细胞和肥大细胞的比例更高。表达M2巨噬细胞的细胞比例更高与更高的组织学分级和更晚期的疾病阶段相关。表达M2巨噬细胞的细胞比例更高与恶性卵巢肿瘤更差的预后相关。发现卵巢癌新的预后因素可能是该疾病新治疗方法和免疫疗法研究的目标。此外，它可以帮助肿瘤学家对预后因素较差的患者采取更积极的治疗措施。
